Dr Michelle Lawson
BSc, PhD, FHEA
Clinical Medicine, School of Medicine and Population Health
School Director of Postgraduate Research
Senior Lecturer in Bone and Cancer Biology
+44 114 215 9054
Full contact details
Clinical Medicine, School of Medicine and Population Health
Office EU22, E Floor
The Medical School
Beech Hill Road
91直播
S10 2RX
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
I graduated from the University of 91直播 in 1997 with a BSc (Hons) in Molecular Biology. I obtained my PhD in 2000 from the University of Bristol, after conducting my research at the Institute of Animal Health, investigating the use of cytokines as DNA vaccine adjuvants.
In 2000 I began my research career in the field of bone biology at the University of Oxford. While there I developed various biomaterials for bone scaffolding and a novel technique to measure the bone binding affinities of bisphosphonates, drugs used in the prevention of bone disease.
In 2005 I moved back to the University of 91直播 where I worked in Professor Peter Croucher鈥檚 Bone Biology Group and my research involved looking at the effects of bisphosphonates in preclinical models of multiple myeloma. I also developed a novel microscopy technique to allow the visualization of single dormant cancer cells in bone. Together this research has led to the identification of several key molecules involved in the early stages of myeloma and its associated bone disease. I am currently a Senior Lecturer in Bone and Cancer Biology in the Department of Oncology and Metabolism and I lead the 91直播 Myeloma Research Team (SMaRT). My main research interests are myeloma-induced bone disease, dormant tumour cells, and the use of oncolytic adenoviruses to combat myeloma and lymphoma.
- Research interests
-
I have developed and established several preclinical murine models of myeloma to study therapeutic intervention in the early, mid and late stages of the disease. This has led to an increased understanding of the role of the bone marrow microenvironment and how it influences tumour growth and tumour cell dormancy. I am currently investigating the use of standard of care anti-myeloma drugs in combination with bone modulating agents to repair myeloma-induced bone disease; and using existing (standard of care therapies) or novel agents (oncolytic viruses) to target myeloma cells (proliferating and dormant) in the bone marrow microenvironment, with the aim of translating these findings into patients. I am currently collaborating with Theolytics to harness viruses to combat myeloma ().
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . Cancers, 13(22).
- . Journal of Clinical Medicine, 10(17).
- . Journal for ImmunoTherapy of Cancer, 9(3).
- . Seminars in Cell & Developmental Biology, 112, 49-58.
- . Oncogene, 39(27), 5001-5014.
- . Journal of Bone and Mineral Research, 34(12), 2311-2326.
- . Journal of Bone and Mineral Research.
- . Journal of Bone and Mineral Research, 32(9), 1860-1869.
- . Nature Communications, 6(1), ---.
- . Bone, 77, 57-68.
- . PLOS ONE, 10(3), e0119546-e0119546.
Chapters
All publications
Journal articles
- . eBioMedicine, 104, 105163-105163.
- . Viruses, 15(3).
- . Clinical Lymphoma Myeloma and Leukemia, 22, S108-S108.
- . Cancers, 13(22).
- . Journal of Bone Oncology, 31, 100398-100398.
- . Journal of Clinical Medicine, 10(17).
- . Journal for ImmunoTherapy of Cancer, 9(3).
- . Journal of Cancer Metastasis and Treatment, 7.
- . Seminars in Cell & Developmental Biology, 112, 49-58.
- . Calcified Tissue International, 107(1), 72-85.
- . Oncogene, 39(27), 5001-5014.
- . JBMR Plus, 4(2).
- . Journal of Bone and Mineral Research, 34(12), 2311-2326.
- . Bone, 124, 166-166.
- . Bone, 122, 82-92.
- . Blood, 132(Supplement 1), 3213-3213.
- . Journal of Bone and Mineral Research.
- . PLoS One, 13(6).
- . Calcified Tissue International, 102(2), 196-209.
- . Journal of Bone and Mineral Research, 32(9), 1860-1869.
- . Haematologica, 102, e336-e339.
- . Bone Abstracts.
- . Bone, 83, 9-16.
- . Nature Communications, 6(1), ---.
- . The FASEB Journal, 29(8), 3141-3150.
- . Bone, 77, 57-68.
- . British Medical Bulletin, 111(1), 117-138.
- . Bone Abstracts.
- . PLoS One, 7(5), e35830.
- . PLoS One, 7(8), e41127.
- . Curr Pharm Des, 16(27), 3028-3036.
- . P NATL ACAD SCI USA, 107(16), 7604-7609.
- . Curr Pharm Des, 16(11), 1272-1283.
- . Journal of Biomedical Materials Research Part B: Applied Biomaterials, 92B(1), 149-155.
- . Developmental & Comparative Immunology, 33(4), 540-546.
- . Biochem Biophys Res Commun, 377(2), 453-457.
- . Cancer Research, 67(10), 4572-4577.
- . Bone, 38(3), 55.
- . Bone, 38(3), 63-64.
- Driving sound science leadership. FOOD TECHNOLOGY, 60(2), 11-11.
- Engaging our younger members. FOOD TECHNOLOGY, 60(5), 11-11.
- Perfecting the partnership paradigm. FOOD TECHNOLOGY, 60(3), 11-11.
- . Journal of Materials Science: Materials in Medicine, 16(6), 515-519.
- . Tissue Engineering, 10(9-10), 1480-1491.
- . Tissue Engineering, 10(9), 1480-1491.
- . Biomaterials, 24(20), 3475-3481.
- . Immunology, 103(1), 106-112.
- . Developmental & Comparative Immunology, 25(1), 69-82.
- . Journal of Interferon & Cytokine Research, 20(2), 161-170.
- . Journal of Medical Entomology, 27(5), 829-834.
- . Life Sciences, 36(18), 1715-1720.
- . Journal of Medical Entomology, 19(4), 361-365.
- NON-CORRELATION OF INSECTICIDE AND REPELLENT TOLERANCES IN REPRESENTATIVE SPECIES AND STRAINS OF MOSQUITOS. MOSQUITO NEWS, 41(4), 684-688.
- . Journal of Medical Entomology, 15(5-6), 452-458.
- REARING OF DIAMANUS-MONTANUS (SIPHONAPTERA, CERATOPHYLLIDAE) AND HOPLOPSYLLUS-ANOMALUS (SIPHONAPTERA, PULICIDAE). JOURNAL OF MEDICAL ENTOMOLOGY, 15(3), 303-303.
- . Archives of Environmental Contamination and Toxicology, 6(1), 23-31.
- A case of "congenital " occlusion of the common hepatic duct in a twin baby, with an indirect van den Berg reaction. LANCET, 2, 113-113.
- . Molecular Cancer Therapeutics.
- . JBMR Plus.
- . The Journal of Neuroscience.
- . Oncogene.
- . PLOS ONE, 10(3), e0119546-e0119546.
- . Journal of Oral Pathology & Medicine.
Chapters
- , Bone Cancer (pp. 35-53). Elsevier
- , Bone Cancer (pp. 1005-1017). Elsevier
- , Encyclopedia of Bone Biology (pp. 180-200). Elsevier
- , The Duration and Safety of Osteoporosis Treatment (pp. 17-36). Springer International Publishing
- , Bone Cancer (pp. 503-518). Elsevier
- , Bone Cancer (pp. xi-xv). Elsevier
- , Bone Cancer: Primary Bone Cancers and Bone Metastases: Second Edition (pp. 503-518).
- , Bone Cancer (pp. 347-363). Elsevier
- , Bone Cancer (pp. xi-xv). Elsevier
- , Bone Cancer (pp. 347-363).
Conference proceedings papers
- Mechanisms of Bone Pain in Multiple Myeloma: Involvement of Periosteal Bone Sprouting. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 55-56)
- Myeloma-induced bone pain: lessons learnt from a localized, immunocompetent mouse model. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol. 22 (pp S108-S108)
- Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
- Preventing and repairing myeloma bone disease by combining zoledronic acid with TGF beta inhibition therapy. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 16-16)
- P2X7R in primary bone cancer. PURINERGIC SIGNALLING, Vol. 14 (pp S13-S14)
- . Experimental Hematology, Vol. 64(Suppl) (pp S74-S75). Los Angeles, USA, 23 August 2018 - 26 August 2018.
- (pp 18-18)
- Evaluating the contribution of anti-myeloma immunity for the efficacy of oncolytic reovirus therapy.. CLINICAL CANCER RESEARCH, Vol. 23(24) (pp 44-44)
- . BONE, Vol. 48(1) (pp S14-S14)
- . BONE, Vol. 48(1) (pp S15-S15)
- . BONE, Vol. 47 (pp S328-S328)
- . BONE, Vol. 44 (pp S162-S162)
- . BONE, Vol. 44 (pp S164-S164)
- Nitrogen-containing bisphosphonates and prediction of their clinical potencies: Dissociation of target enzyme- and hydroxyapatite-binding affinities. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1125-1125)
- Predicting pharmacological potencies of nitrogen-containing bisphosphonates; novel methods dissociate enzyme- and hydroxyapatite-binding affinities. BONE, Vol. 40(6) (pp S301-S302)
- Predicting the clinical potencies of bisphosphonates: Divergence of hydroxyapatite and farnesyl diphosphate synthase binding affinities. CALCIFIED TISSUE INTERNATIONAL, Vol. 80 (pp S155-S155)
- Risedronate prevents bone disease and reduces turnour burden in a syngeneic model of multiple myeloma.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S137-S137)
- Refining structure activity relationships among nitrogen containing bisphosphonates: Dissociation of mineral binding affinity and inhibitory potency on farnesyl diphosphate synthase.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S183-S183)
- A novel method to characterize relative mineral binding affinities of bisphosphonates and the structural requirements for binding by using ceramic hydroxyapatite column chromatography.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S191-S191)
- Risedronate prevents bone disease and reduces tumour burden in a syngeneic model of multiple myeloma. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1160-1160)
- Substitutions in the R1 hydroxyl and C1 phosphate positions significantly affect binding of risedronate during hydroxyapatite ceramic chromatography. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1168-1168)
- Risedronate prevents bone disease and reduces tumour burden in a syngeneic model of multiple myeloma. CANCER TREATMENT REVIEWS, Vol. 32 (pp S35-S35)
- Potential bone mineral binding differences among bisphosphonates can be demonstrated by the use of hydroxyapatite column chromatography.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S396-S396)
- Differences in the potential binding of phosphate containing compounds to bone mineral are revealed by the novel use of hydroxyapatite column chromatography. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(7) (pp 1303-1303)
- The use of hydroxyapatite column chromatography as a novel method to reveal differences in relative binding affinities of bisphosphonates. BONE, Vol. 36 (pp S308-S309)
- Comparison of 2D and 3D bone marrow cell growth on alginate hydrogels. Transactions - 7th World Biomaterials Congress (pp 154)
- Behaviour of bone marrow stromal cells on and within alginate gels for potential use in tissue engineering procedures. Transactions - 7th World Biomaterials Congress (pp 913)
- PREDICTORS OF MORTALITY AT HOSPITAL DISCHARGE AND AT ONE-YEAR FOR PATIENTS PRESENTING TO TERTIARY CARE HOSPITALS WITH MYOCARDIAL-INFARCTION. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (pp A296-A296)
- OPTIMIZING THE METHOD TO CALCULATE RIGHT-VENTRICULAR EJECTION FRACTION FROM 1ST PASS DATA. CIRCULATION, Vol. 90(4) (pp 365-365)
- CORRELATION OF THALLIUM UPTAKE WITH LEFT-VENTRICULAR WALL THICKNESS BY CINE MRI IN PATIENTS WITH MYOCARDIAL INFARCTIONS. CIRCULATION, Vol. 90(4) (pp 365-365)
- ACCURACY OF BIPLANE LONG AXIS CINE MRI VOLUMES IN PATIENTS WITH REGIONAL AND GLOBAL LEFT-VENTRICULAR DYSFUNCTION. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (pp A90-A90)
- MULTISLICE MRI IN THE ASSESSMENT OF MYOCARDIAL PERFUSION - A COMPARISON WITH RADIONUCLIDE METHODS. CIRCULATION, Vol. 90(4) (pp 411-411)
- DO PREDICTORS OF MORTALITY AT ONE-YEAR DIFFER FROM THOSE AT HOSPITAL DISCHARGE FOR PATIENTS PRESENTING WITH MYOCARDIAL-INFARCTION. CLINICAL RESEARCH, Vol. 41(4) (pp A781-A781)
- HISTORICAL AND CLINICAL PREDICTORS OF IN-HOSPITAL DEATH AND REINFARCTION IN PATIENTS PRESENTING WITH PROLONGED CHEST PAIN. CLINICAL RESEARCH, Vol. 40(4) (pp A805-A805)
- WIDESPREAD DISTRIBUTION OF CHOLINESTERASE ACTIVITY IN GREEN PLANTS. FEDERATION PROCEEDINGS, Vol. 41(4) (pp 1146-1146)
- SPONTANEOUS REACTIVATION OF HUMAN-SERUM CHOLINESTERASE INHIBITED BY SELECTED ORGANOPHOSPHINATES. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, Vol. 183(MAR) (pp 15-MEDI)
- GENERAL APPLICATIONS OF PROGRAMMABLE DESK TOP CALCULATOR. JOURNAL OF NUCLEAR MEDICINE, Vol. 15(6) (pp 511-511)
Preprints
- Grants
-
- Innovate UK award (UK Biomedical Catalyst 2022-2025) Preclinical validation of a novel oncolytic viral therapy for multiple myeloma targeting readiness for clinical trials. Dr M.A. Lawson & Dr A.D. Chantry (拢127,545).&苍产蝉辫;10017183
- 91直播 Hospitals Charity Project Award (2021-2022). Treating plasmacytoma using direct injection of a novel engineered myeloma specific virus. Dr M.A. Lawson (拢24,275). No. 173173
- 91直播 Hospitals Charity Project Award (2021-2022). The effect of targeting hepatocyte growth factor (HGF) combined with chemotherapy on tumour load in myeloma. Dr M.A. Lawson (拢13,891). No. 173345
- NC3Rs studentship award (2021-2023). Development and validation of 3D in vitro dormant myeloma cell models to reduce and replace animal studies. Dr M.A. Lawson, Alana Green & Frederik Claeyssens (拢90,000). NC/V00137X/1
- 91直播 Hospitals Charity Project Award (2021-2022). Targeting minimal residual disease to find a cure for myeloma. Dr A. Green, Dr A.D. Chantry, Dr M.A. Lawson (拢42,862). No. 169591
- 91直播 Hospitals Charity Project Award (2020-2021). Assessing SD208 (a novel bone anabolic agent) as equivalent or superior in the treatment of myeloma bone; an in vivo explorative study. Dr R. Andrews, Dr Chantry & Dr M.A. Lawson (拢41,000). 163969
- 91直播 Hospitals Charity Project Award (2020-2021). Oncolytic advenovirus therapy for multiple myeloma. Dr Chantry & Dr M.A. Lawson (拢41,143). No. 202014
- Oxford Biomedica (2019-2020) Clinical collaboration using CAR-T cells therapy. Dr M. A. Lawson (拢13,400).
- Shin Poong Pharma (2017-2018). Testing a potential bone anabolic agent (SP-35454) in multiple myeloma, Dr M. A. Lawson (拢140,000).
- Bone Cancer Research Trust (2015-2018). PhD studentship: Purinergic Signalling in Osteosarcoma, Dr A. Gartland & Dr M.A. Lawson (拢147,000). BCRT Grant No. 44/15.
- British Association of Oral and Maxillofacial Surgeon (2106-218) Project Grant: Investigating the potential of statins to prevent and treat Anti-Resorptive agent induced Osteonecrosis of the Jaw, Dr M. A. Lawson, Ibraz Siddique & Alasdair McKechnie (拢6384).
- 91直播 Blood Cancer Trust (2015). High potency, low affinity bisphosphonates pilot study, Dr A. Chantry, Dr M.A. Lawson, Prof. J. Snowden& Prof R.G.G. Russell (拢8,000).
- 91直播 Hospitals Charity (2015). Investigating changes in the tumour bone microenvironment during the development of multiple myeloma and testing novel strategies for clinical intervention. Dr M.A. Lawson, J. Paton-Hough (91直播) & Dr F. Errington-Mais (University of Leeds) (拢4,739).
- Bloodwise Project Grant (2018-2020). Targeting BMP signalling in the MGUS/MM bone microenvironment. Dr C. Edwards, Dr K. Ramasamy, Dr M.A. Lawson, H. Drakesmith, Dr S. Gooding & R. Kumar grant (拢249,691). Grant no. 17012.
- Bloodwise Project Grant Investigating (2016-2019). E3 Ligase HUWE1 as a therapeutic target in multiple myeloma.Dr A. Irvine, Dr M.A. Lawson, M. Pearson, Dr L. Crawford, Prof M. Eilers & Dr A. Chantry (拢202,080). Grant no. 15043.
- Bloodwise Project Grant (2015-2018). Preclinical testing of low dose valproate and niclosamide (VaN) as a novel anti-myeloma therapy. Dr F. Khanim, Dr M.A. Lawson& Prof. M Drayson (拢245,864). Grant No. 15025.
- Bloodwise Specialist Programme Grant (2013-2018). Novel targets and therapeutic combinations in myeloma. Dr A. Chantry, Dr M.A. Lawson & Prof. J. Snowden (拢1,142,591). Grant No. 12053.
- Teaching interests
-
I am a Fellow of the Higher Education Academy (FHEA) and the Postgraduate Research (PGR) Lead in the Department of Oncology and Metabolism. I am also a Module Lead for the MSc (Res) in Translational Oncology course and I regularly lecture on the Molecular Medicine MSc course on in vitro and in vivo models of bone cancer. I frequently supervise laboratory research projects for PhD, MSc, BMedSci, SSC, Erasmus and Hallam placement students.
- Professional activities and memberships
-
I have been involved in several public engagement activities. I have secured funding that enabled me to build a 鈥淕iant Interactive Bone鈥 to educate children of all ages on what is inside their bones. In addition, I regularly participate in Outreach activities with a variety of school children to teach them about why their bones are so important. I frequently do laboratory tours for fundraisers and patients with bone cancer, and I also participate in patient panel meetings to improve the services at the Royal Hallamshire Hospital in 91直播.
- Public engagement activities
I have also been involved in a number of public engagement activities. I have secured funding that enabled me to build a 鈥淕iant Interactive Bone鈥 to educate children of all ages on what is inside their bones. In addition, I regularly participate in Outreach activities with a variety of school children to teach them about why their bones are so important. I frequently do laboratory tours for fundraisers and patients with bone cancer, and I also participate in patient panel meetings to improve the services at the Royal Hallamshire Hospital in 91直播.